$1.79 Earnings Per Share Expected for Mallinckrodt PLC (MNK) This Quarter

Wall Street brokerages expect Mallinckrodt PLC (NYSE:MNK) to announce $1.79 earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Mallinckrodt’s earnings, with estimates ranging from $1.70 to $1.98. Mallinckrodt posted earnings of $1.31 per share during the same quarter last year, which would suggest a positive year over year growth rate of 36.6%. The firm is expected to report its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Mallinckrodt will report full-year earnings of $8.20 per share for the current year, with EPS estimates ranging from $8.10 to $8.32. For the next fiscal year, analysts forecast that the company will report earnings of $7.64 per share, with EPS estimates ranging from $6.32 to $8.79. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Mallinckrodt.

Mallinckrodt (NYSE:MNK) last announced its quarterly earnings results on Tuesday, February 26th. The company reported $2.18 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.20. Mallinckrodt had a negative net margin of 134.63% and a positive return on equity of 11.14%. The firm had revenue of $834.90 million during the quarter, compared to analysts’ expectations of $681.45 million. During the same period in the previous year, the company earned $2.01 earnings per share. Mallinckrodt’s quarterly revenue was up 5.4% compared to the same quarter last year.

MNK has been the subject of a number of research reports. Zacks Investment Research raised shares of Mallinckrodt from a “hold” rating to a “strong-buy” rating and set a $21.00 target price for the company in a report on Tuesday, January 8th. ValuEngine cut shares of Mallinckrodt from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. Morgan Stanley set a $32.00 target price on shares of Mallinckrodt and gave the company a “hold” rating in a report on Thursday, February 28th. Mizuho reaffirmed a “neutral” rating on shares of Mallinckrodt in a report on Monday, December 17th. Finally, Wells Fargo & Co set a $27.00 target price on shares of Mallinckrodt and gave the company a “hold” rating in a report on Friday, December 7th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $31.44.

Institutional investors have recently modified their holdings of the company. Oregon Public Employees Retirement Fund increased its stake in shares of Mallinckrodt by 1,480.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 520,326 shares of the company’s stock worth $33,000 after acquiring an additional 487,394 shares during the period. FNY Investment Advisers LLC increased its stake in shares of Mallinckrodt by 210.4% during the fourth quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock worth $36,000 after acquiring an additional 1,551 shares during the period. We Are One Seven LLC acquired a new position in shares of Mallinckrodt during the fourth quarter worth about $38,000. QS Investors LLC increased its stake in shares of Mallinckrodt by 14.3% during the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock worth $64,000 after acquiring an additional 500 shares during the period. Finally, Quantamental Technologies LLC acquired a new position in shares of Mallinckrodt during the fourth quarter worth about $80,000.

MNK traded up $0.08 on Thursday, reaching $22.00. The company had a trading volume of 785,195 shares, compared to its average volume of 1,857,984. Mallinckrodt has a 1 year low of $11.65 and a 1 year high of $36.65. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.51 and a quick ratio of 1.17. The stock has a market cap of $1.82 billion, a PE ratio of 2.75, a price-to-earnings-growth ratio of 0.22 and a beta of 2.31.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Further Reading: What is Compound Interest?

Get a free copy of the Zacks research report on Mallinckrodt (MNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.